Search

Your search keyword '"Xinying, Xue"' showing total 3 results
Start Over Author "Xinying, Xue" Journal frontiers in oncology
3 results on '"Xinying, Xue"'

1. PIWI-interacting RNAs in cancer: Biogenesis, function, and clinical significance

Author

Jie Yao, Mei Xie, Xidong Ma, Jialin Song, Yuanyong Wang, and Xinying Xue

Subjects
piRNA, PIWI, cancer, biomarkers, diagnosis, prognosis, Neoplasms. Tumors. Oncology. Including cancer and carcinogens, RC254-282
Abstract

PIWI-interacting RNAs (piRNAs) are a less-studied class of small non-coding RNAs approximately 24–31 nucleotides in length. They express in germline and somatic cells and form complexes with PIWI proteins to exert regulatory effects. New studies show that piRNAs are aberrantly expressed in various cancers. In this review, we focus on those piRNAs that are associated with cancer hallmarks such as proliferation, invasion, and chemoresistance and discuss their potential as biomarkers for cancer diagnosis and prognosis.

Published
2022
Full Text
View/download PDF

2. Catalog of Lung Cancer Gene Mutations Among Chinese Patients

Author

Xinying Xue, Idorenyin Asuquo, Lei Hong, Jie Gao, Zhouhuan Dong, Li Pang, Tianjiao Jiang, Mingming Meng, Jingbo Fan, Jiaxin Wen, Hui Deng, Xuelei Zang, Xidong Ma, Rui Guo, Chong Qin, Yao Meng, Heji Ma, Jun Han, Haijiao Wang, Zhiqiang Xue, Dahai Zhao, Dongliang Lin, and Lei Pan

Subjects
lung cancer, China, gene mutation, aging, tobacco smoking, pathology, Neoplasms. Tumors. Oncology. Including cancer and carcinogens, RC254-282
Abstract

Background: Detailed catalog of lung cancer-associated gene mutations provides valuable information for lung cancer diagnosis and treatment. In China, there has never been a wide-ranging study cataloging lung cancer-associated gene mutations. This study aims to reveal a comprehensive catalog of lung cancer gene mutations in china, focusing on EGFR, ALK, KRAS, HER2, PIK3CA, MET, BRAF, HRAS, and CTNNB1 as major targets. Additionally, we also aim to correlate smoking history, gender, and age distribution and pathological types with various types of gene mutations.Patients and Methods: A retrospective data acquisition was conducted spanning 6 years (2013–2018) among all patients who underwent lung cancer surgeries not bronchial or percutaneous lung biopsy at three major tertiary hospitals. Finally, we identified 1,729 patients who matched our inclusion criteria.Results: 1081 patients (62.49%) harbored EGFR mutation. ALK (n = 42, 2.43%), KRAS (n = 201, 11.62%), CTNNB1 (n = 28, 1.62%), BRAF (n = 31, 1.79%), PIK3CA (n = 51, 2.95%), MET (n = 14, 0.81%), HER2 (n = 47, 2.72%), HRAS (n = 3, 0.17%), and other genes(n = 232, 13.4%). Females expressed 55.38% vs. males 44.62% mutations. Among subjects with known smoking histories, 32.82% smokers, 67.15% non-smokers were observed. Generally, 51.80% patients were above 60 years vs. 48.20% in younger patients. Pathological types found includes LUADs 71.11%, SQCCs 1.68%, ASC 0.75%, LCC 0.58%, SCC 0.35%, ACC 0.17%, and SC 0.06%, unclear 25.19%.Conclusion: We offer a detailed catalog of the distribution of lung cancer mutations. Showing how gender, smoking history, age, and pathological types are significantly related to the prevalence of lung cancer in China.

Published
2020
Full Text
View/download PDF

3. Catalog of Lung Cancer Gene Mutations Among Chinese Patients

Author

Xidong Ma, Dahai Zhao, Xuelei Zang, Zhouhuan Dong, Jun Han, Tianjiao Jiang, Haijiao Wang, Xinying Xue, Jiaxin Wen, Heji Ma, Zhiqiang Xue, Idorenyin Polycarp Asuquo, Yao Meng, Jie Gao, Rui Guo, Chong Qin, Li Pang, Dongliang Lin, Lei Hong, Jingbo Fan, Mingming Meng, Hui Deng, and Lei Pan

Subjects
0301 basic medicine, Oncology, Cancer Research, medicine.medical_specialty, China, Lung biopsy, Gene mutation, medicine.disease_cause, lcsh:RC254-282, Retrospective data, 03 medical and health sciences, 0302 clinical medicine, Internal medicine, medicine, HRAS, gene mutation, tobacco smoking, Lung cancer, Pathological, Original Research, Lung, business.industry, aging, medicine.disease, lcsh:Neoplasms. Tumors. Oncology. Including cancer and carcinogens, lung cancer, 030104 developmental biology, medicine.anatomical_structure, 030220 oncology & carcinogenesis, pathology, KRAS, business
Abstract

Background: Detailed catalog of lung cancer-associated gene mutations provides valuable information for lung cancer diagnosis and treatment. In China, there has never been a wide-ranging study cataloging lung cancer-associated gene mutations. This study aims to reveal a comprehensive catalog of lung cancer gene mutations in china, focusing on EGFR, ALK, KRAS, HER2, PIK3CA, MET, BRAF, HRAS, and CTNNB1 as major targets. Additionally, we also aim to correlate smoking history, gender, and age distribution and pathological types with various types of gene mutations. Patients and Methods: A retrospective data acquisition was conducted spanning 6 years (2013-2018) among all patients who underwent lung cancer surgeries not bronchial or percutaneous lung biopsy at three major tertiary hospitals. Finally, we identified 1,729 patients who matched our inclusion criteria. Results: 1081 patients (62.49%) harbored EGFR mutation. ALK (n = 42, 2.43%), KRAS (n = 201, 11.62%), CTNNB1 (n = 28, 1.62%), BRAF (n = 31, 1.79%), PIK3CA (n = 51, 2.95%), MET (n = 14, 0.81%), HER2 (n = 47, 2.72%), HRAS (n = 3, 0.17%), and other genes(n = 232, 13.4%). Females expressed 55.38% vs. males 44.62% mutations. Among subjects with known smoking histories, 32.82% smokers, 67.15% non-smokers were observed. Generally, 51.80% patients were above 60 years vs. 48.20% in younger patients. Pathological types found includes LUADs 71.11%, SQCCs 1.68%, ASC 0.75%, LCC 0.58%, SCC 0.35%, ACC 0.17%, and SC 0.06%, unclear 25.19%. Conclusion: We offer a detailed catalog of the distribution of lung cancer mutations. Showing how gender, smoking history, age, and pathological types are significantly related to the prevalence of lung cancer in China.

Published
2020
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results